This e-learning course discusses treatment sequencing in advanced hepatocellular carcinoma (HCC). Key clinical questions will be addressed, including:

  • What does the current systemic treatment landscape for advanced HCC look like?
  • What is the role of novel systemic therapies and immunotherapy?
  • What is the impact of treatment sequencing?
  • What are the main adverse events associated with targeted therapy and immunotherapy, including immune-related hepatotoxicity?
  • What will be the future role of tissue-based biomarkers in HCC?

This e-learning course discusses the changing treatment landscape in hepatocellular carcinoma (HCC) and how therapy can be optimised for the individual patient. Key clinical questions will be addressed, including;

  • When and how to transition from loco-regional to systemic therapy?
  • What is the role of novel systemic therapies and immunotherapy?
  • What is the impact of treatment sequencing?

During the e-learning, Experts will present different patient case studies to enhance your understanding of this area.

EACCME 認定

https://checkpoint.cor2ed.com で利用可能で、COR2ED が組織している COR2ED Checkpoint は、医療専門家に次の CME アクティビティを提供するために、European Accreditation Council for Continuing Medical Education (EACCME) の認定を受けています。

各医療専門家は、教育アクティビティを実際に行った単位のみを要求すべきです。EACCME は、European Union of Medical Specialists (UEMS) の機関です。UEMS-EACCME ウェブサイトに表示されている e-ラーニング資料のみが、公式認定を受けています。

European Union of Medical Specialists (UEMS) と American Medical Association (AMA) の間の同意を通して、医師は EACCME の単位を、同等数の AMA PRA Category 1 Credits™ に変換することができます。

EACCME 単位を AMA 単位に変換するプロセスに関する情報は www.ama-assn.org/education/earn-credit-participation-international-activities.